Thrivent Financial For Lutherans Exact Sciences Corp Transaction History

Thrivent Financial For Lutherans

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$62.68 - $95.05 $40,992 - $62,162	-654 Reduced 2.76%	23,030 $2.16 Million
Q1 2023 May 17, 2023	BUY	$47.19 - $70.77 $258,129 - $387,111	5,470 Added 30.03%	23,684 $1.61 Million
Q4 2022 Feb 08, 2023	BUY	$30.35 - $53.15 $273,028 - $478,137	8,996 Added 97.59%	18,214 $904,000
Q2 2022 Aug 16, 2022	SELL	$35.61 - $76.23 $265,543 - $568,447	-7,457 Reduced 44.72%	9,218 $363,000
Q1 2022 May 13, 2022	SELL	$57.56 - $82.54 $112,760 - $161,695	-1,959 Reduced 10.51%	16,675 $1.17 Million
Q4 2021 Feb 16, 2022	BUY	$72.5 - $100.68 $1.35 Million - $1.88 Million	18,634 New	18,634 $1.54 Million
Q3 2021 Nov 15, 2021	SELL	$90.24 - $124.05 $176,780 - $243,013	-1,959 Closed	0 $0
Q2 2021 Sep 24, 2021	BUY	$93.66 - $139.27 $183,479 - $272,829	1,959 New	1,959 $244,000
Q2 2021 Aug 19, 2021	SELL	$93.66 - $139.27 $179,265 - $266,562	-1,914 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$116.57 - $155.01 $582 - $775	5 Added 0.26%	1,914 $252,000
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $11,953 - $17,054	-120 Reduced 5.91%	1,909 $253,000
Q3 2020 Nov 10, 2020	BUY	$72.92 - $102.01 $147,954 - $206,978	2,029 New	2,029 $207,000

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.